ライフサイエンスコーパス: ceftazidime

1 d false resistance (aztreonam, cefepime, and ceftazidime).

2 ithout the antibiotic treatment (imipenem or ceftazidime).

3 me, and ceftriaxone, and 1 for cefazolin and ceftazidime).

4 t beta-lactam antibiotics, carbenicillin and ceftazidime.

5 imino-cephalosporins, such as cefotaxime and ceftazidime.

6 d susceptible to cefotaxime, ceftriaxone, or ceftazidime.

7 ration cephalosporins such as cefotaxime and ceftazidime.

8 oximino cephalosporins such as cefotaxime or ceftazidime.

9 level resistance to the structurally similar ceftazidime.

10 eftazidime, or isotype control antibody with ceftazidime.

11 th injection of intravitreous vancomycin and ceftazidime.

12 he absence of simultaneous administration of ceftazidime.

13 plus amoxicillin-clavulanate or intravenous ceftazidime.

14 oplastic agents, cefotaxime, vancomycin, and ceftazidime.

15 cefotaxime and the gram-negative spectrum of ceftazidime.

16 extended-spectrum antibiotics cefotaxime and ceftazidime.

17 the 92 children had never been treated with ceftazidime.

18 92 harboured isolates that were resistant to ceftazidime.

19 ty for extended-spectrum antibiotics such as ceftazidime.

20 ii by BOCILLIN FL, aztreonam, meropenem, and ceftazidime.

21 nly a modest 25% increase in k(cat)/K(m) for ceftazidime (0.015-->0.019 mum(-1) s(-1)).

22 every 6 hrs, cefepime 1 g every 12 hrs, and ceftazidime 1 g every 8 hrs with target attainments of 9

23 anisms, susceptibilities were the following: ceftazidime, 100%; levofloxacin, 100%; ciprofloxacin, 95

24 d by carbapenems (20%), TMP-SMX (18.5%), and ceftazidime (11%).

25 ztreonam, >128 microg/ml versus 4 microg/ml; ceftazidime, 128 microg/ml versus 2 microg/ml; piperacil

26 Ceftazidime 1g every 8 hrs and ciprofloxacin produce low

27 9.9%, followed by cefepime 2 g every 12 hrs, ceftazidime 2 g every 8 hrs, piperacillin/tazobactam 4.5

28 d-inject procedures with vancomycin 1 mg and ceftazidime 2 mg.

29 Meropenem, imipenem, cefepime, ceftazidime (2 g every 8 hrs), and piperacillin/tazobact

30 g/8 hours) plus daptomycin (6 mg/kg/day) or ceftazidime (2 g/8 hours).

31 na vitrectomy with intravitreal injection of ceftazidime (2 mg/0.1 ml) and amikacin (0.4 mg/0.1 ml) w

32 I) and BHI plus vancomycin (6 microg/ml) and ceftazidime (2 microg/ml) (BHIVC).

33 th 5% sheep blood, vancomycin (6 microg/ml), ceftazidime (2 microg/ml), amphotericin B (2 microg/ml),

34 he 94 gram-negative organisms tested against ceftazidime, 2 were of intermediate sensitivity and 6 we

35 ients were randomized to receive intravenous ceftazidime (2000 mg) plus tobramycin (1 mg/kg) every 8

36 E. coli 018:K1 in the presence or absence of ceftazidime (50 mg/kg intravenously).

37 for cefepime; 44 and 43%, respectively, for ceftazidime; 71 and 19%, respectively, for imipenem; and

38 d standard concentrations of aztreonam (78), ceftazidime (79), ceftriaxone (83), or cefpodoxime (98)

39 parentheses): DD method with aztreonam (95), ceftazidime (79), ceftriaxone (88), or cefpodoxime (90);

40 doxime (90); broth microdilution method with ceftazidime (86) or cefotaxime (91) alone or in combinat

41 (98) or a novel concentration (5 microg) of ceftazidime (88).

42 omitant 4-fold increase in the resistance to ceftazidime, a third-generation cephalosporin.

43 ctamase activity that increased tolerance to ceftazidime, a widely used beta-lactam antibiotic.

44 ucted to explain these findings suggest that ceftazidime adopts a unique conformation, despite preser

45 -lactam antibiotics, such as amoxicillin and ceftazidime, against bacteria expressing class C beta-la

46 e gradient technology to evaluate the MIC of ceftazidime alone compared with the MIC of ceftazidime w

47 had a safety profile consistent with that of ceftazidime alone.

48 onsistent with that previously observed with ceftazidime alone.

49 oncentrations and hydrolytic activity toward ceftazidime, an advanced generation cephalosporin antibi

50 sequence requirements for the hydrolysis of ceftazidime, an extended spectrum cephalosporin commonly

51 ile prediction of resistance was 69%-73% for ceftazidime and 41%-50% for imipenem.

52 ies, were randomly assigned (1:1) to 2000 mg ceftazidime and 500 mg avibactam (by 2 h intravenous inf

53 and to receive either systemic antibiotics (ceftazidime and amikacin) or no systemic antibiotics.

54 olderia pseudomallei had subpopulations with ceftazidime and amoxicillin-clavulanate susceptibilities

55 Ceftazidime and aztreonam disks were equivalent in diffe

56 237G substitution in differentiating between ceftazidime and aztreonam was further investigated by ki

57 d increases in catalytic efficiency for both ceftazidime and aztreonam.

58 tests, this cephalothin analogue lowered the ceftazidime and cefotaxime minimum inhibitory concentrat

59 esponsible for the improved activity against ceftazidime and cefotaxime, consistent with observations

60 t one ESC were tested by disk diffusion with ceftazidime and cefotetan disks with and without APBA.

61 1-255 significantly enhanced the activity of ceftazidime and cefpirome against extended-spectrum ceph

62 s (MK-7655 with imipenem, and avibactam with ceftazidime and ceftaroline), new macrolides (cethromyci

63 ulated binding of the substrates ampicillin, ceftazidime and imipenem suggests that the substrate is

64 Comparison of the acyl-enzyme structures of ceftazidime and loracarbef, a beta-lactam substrate, rev

65 Susceptibility to ceftazidime and meropenem occurred in approximately 70%

66 ised with P aeruginosa that was resistant to ceftazidime and other beta-lactam antibiotics.

67 residue and also of Tyr221 that would allow ceftazidime and other third-generation cephalosporins to

68 The first (21300) expressed resistance to ceftazidime and piperacillin-tazobactam.

69 ater for the extended-spectrum cephalosporin ceftazidime and the monobactam aztreonam.

70 cept for the CTX-M-10-producing E. coli with ceftazidime and the SHV-18-producing K. pneumoniae with

71 and more efficacious than the combination of ceftazidime and tobramycin for the initial empiric treat

72 ng up to a 64-fold increased activity toward ceftazidime and up to an 8-fold increased resistance to

73 plex with the third-generation cephalosporin ceftazidime and with a transition-state analogue of ceft

74 nded-spectrum beta-lactam antibiotics (e.g., ceftazidime) and beta-lactamase inhibitors (e.g., clavul

75 994 14% were resistant to penicillin, 12% to ceftazidime, and 24% to trimethoprim-sulfamethoxazole.

76 for susceptibility to aztreonam, cefotaxime, ceftazidime, and cefoxitin.

77 MIC values of meropenem, doxycycline, ceftazidime, and ceftriaxone for BLNAR strains were two-

78 amase (ESBL) and vancomycin, amphotericin B, ceftazidime, and clindamycin (VACC) plates.

79 sed activity for the oxyimino-cephalosporin, ceftazidime, and decreased activity toward all other bet

80 ed high mortality, significant resistance to ceftazidime, and limited use of TMP-SMX.

81 The size of the endemic reservoir of ceftazidime- and tobramycin-resistant organisms was dete

82 isotype control monoclonal antibody without ceftazidime, anti-CD14 monoclonal antibody with ceftazid

83 detect these isolates if both cefotaxime and ceftazidime are tested, but only about half would be cla

84 penem plus daptomycin is more effective than ceftazidime as empirical antibiotic treatment of nosocom

85 e mode of action of the frontline antibiotic ceftazidime at the molecular level.

86 at the test-of-cure visit were similar with ceftazidime-avibactam (140 [91%; 95% CI 85.6-94.7] of 15

87 Of these, 154 assigned to ceftazidime-avibactam (144 with complicated urinary trac

88 treatment-emergent adverse events with both ceftazidime-avibactam (21 [13%] of 164 patients) and bes

89 (1:1) to 5-21 days of treatment with either ceftazidime-avibactam (a combination of 2000 mg ceftazid

90 -lactam/beta-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resista

91 /acute pyelonephritis were randomized 1:1 to ceftazidime-avibactam 2000 mg/500 mg every 8 hours or do

92 333 patients were randomly assigned, 165 to ceftazidime-avibactam and 168 to best available therapy.

93 program compared the efficacy and safety of ceftazidime-avibactam and doripenem in patients with com

94 andomized patients, 393 and 417 treated with ceftazidime-avibactam and doripenem, respectively, were

95 These results support a role for ceftazidime-avibactam as a potential alternative to carb

96 results provide evidence of the efficacy of ceftazidime-avibactam as a potential alternative to carb

97 ss the efficacy, safety, and tolerability of ceftazidime-avibactam compared with best available thera

98 llin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infectio

99 events occurred in 75 (19%) patients in the ceftazidime-avibactam group and 54 (13%) patients in the

100 51 (31%) of 164 patients in the ceftazidime-avibactam group and 66 (39%) of 168 in the b

101 occurred in 302 (75%) of 405 patients in the ceftazidime-avibactam group versus 299 (74%) of 403 in t

102 pulation, 245 (68.8%) of 356 patients in the ceftazidime-avibactam group were clinically cured, compa

103 Four serious adverse events (all in the ceftazidime-avibactam group) were judged to be treatment

104 57 participants were clinically cured in the ceftazidime-avibactam group, compared with 211 (78.1%) o

105 Ceftazidime-avibactam had a safety profile consistent wi

106 e aimed to assess the efficacy and safety of ceftazidime-avibactam in patients with nosocomial pneumo

107 Ceftazidime-avibactam is a potential new agent for use i

108 oving meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam is unknown.

109 Clinical cure rates with ceftazidime-avibactam plus metronidazole and meropenem,

110 The clinical cure rate with ceftazidime-avibactam plus metronidazole for ceftazidime

111 randomization, assessed by noninferiority of ceftazidime-avibactam plus metronidazole to meropenem in

112 The safety profile of ceftazidime-avibactam plus metronidazole was consistent

113 Ceftazidime-avibactam plus metronidazole was noninferior

114 Ceftazidime-avibactam plus metronidazole was noninferior

115 Efficacy and safety of ceftazidime-avibactam plus metronidazole were compared w

116 Ceftazidime-avibactam resistance was detected in 30% (3/

117 ary endpoint) occurred in 304 of 393 (77.4%) ceftazidime-avibactam vs 296 of 417 (71.0%) doripenem pa

118 Noninferiority of ceftazidime-avibactam vs doripenem was demonstrated for

119 Ceftazidime-avibactam was highly effective for the empir

120 INTERPRETATION: Ceftazidime-avibactam was non-inferior to meropenem in t

121 s for meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam.

122 ae (CRE)-infected patients were treated with ceftazidime-avibactam.

123 id, oritavancin, ceftolozane-tazobactam, and ceftazidime-avibactam.

124 ns of meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam.

125 The strain was highly resistant to ceftazidime-avibactam.

126 No new safety concerns were identified for ceftazidime-avibactam.

127 In summary, ceftolozane/tazobactam and ceftazidime/avibactam are 2 new second-generation cephal

128 Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel beta-lactam/beta-lacta

129 Both ceftolozane/tazobactam and ceftazidime/avibactam are only available as intravenous

130 Ceftazidime/avibactam is also active against carbapenem-

131 ationalize the observed clinical efficacy of ceftazidime/avibactam plus aztreonam as combination ther

132 eta-lactamase inhibitor combinations such as ceftazidime/avibactam, no class B carbapenemases were mi

133 This strain was resistant to ceftazidime, azlocillin, and imipenem, and sensitive to

134 the transition-state analogue suggests that ceftazidime blocks formation of the tetrahedral transiti

135 12-fold decrease in catalytic efficiency for ceftazidime but a 3-fold increase for aztreonam relative

136 The second (26139) expressed resistance to ceftazidime but remained susceptible to piperacillin-taz

137 stance to the third-generation cephalosporin ceftazidime by an uncommon covalent-trapping mechanism.

138 rmational change occurred in the turnover of ceftazidime by KPC-2, but not the R164S variant, providi

139 Ceftazidime cannot adopt a conformation competent for ca

140 nism of resistance to the cephalosporin drug ceftazidime caused by loss of a penicillin-binding prote

141 entiate the activity of cefotaxime (CTX) and ceftazidime (CAZ) against resistant clinical isolates (M

142 l patient surveillance cultures screened for ceftazidime (CAZ) resistance, antibiotic and hospital ex

143 (IPM), meropenem (MEM), ertapenem (ERT), and ceftazidime (CAZ).

144 ening criteria for potential ESBL producers (ceftazidime [CAZ] or cefotaxime [CTX] MICs were > or =2

145 tis to vancomycin (VAN), amikacin (AMK), and ceftazidime (CEF).

146 ected to cefazolin, ceftriaxone, cefotaxime, ceftazidime, cefepime, and aztreonam agar dilution MIC d

147 our antimicrobial agents, namely, cefazolin, ceftazidime, cefepime, and doripenem, were determined by

148 ndard doses: meropenem, imipenem-cilastatin, ceftazidime, cefepime, piperacillin/tazobactam, and cipr

149 er panel and isolates of K. oxytoca, MICs of ceftazidime, cefotaxime, and ceftizoxime were elevated f

150 , using broth microdilution methodology with ceftazidime, cefotaxime, cefepime, cefpodoxime, and aztr

151 MD), and those isolates for which the MIC of ceftazidime, cefotaxime, ceftriaxone, or aztreonam was >

152 For a ceftazidime, ceftriaxone, or cefotaxime MIC of > or =2 m

153 phylococcus aureus killed during imipenem or ceftazidime chemotherapy in mice elicited an early relea

154 Ps, as suggested by a comparison of the PBP3/ceftazidime complex and the Escherichia coli PBP1b/cefto

155 of three beta-lactams (oxacillin, cefepime, ceftazidime) complexes with PBP2a-each with the beta-lac

156 uid chromatography was used to determine the ceftazidime concentrations in the serum and dialysate sa

157 traperitoneal dosing demonstrated that serum ceftazidime concentrations reached therapeutic (> 8 micr

158 Ceftazidime contains a large, bulky side chain that does

159 ould have been reported to be susceptible to ceftazidime, depending upon the routine susceptibility m

160 With a 5-micrograms ceftazidime disk, a breakpoint could be chosen with high

161 Ceftazidime disks with and without clavulanic acid (CLAV

162 Simulation of a variety of ceftazidime dosing regimens using the mean pharmacokinet

163 is usually treated with two or more weeks of ceftazidime followed by oral antibiotics for three to si

164 o once or three-times daily tobramycin (with ceftazidime) for 14 days.

165 acy if given once or three-times daily (with ceftazidime) for pulmonary exacerbations of cystic fibro

166 rescribing a third generation cephalosporin (ceftazidime) for the empiric treatment of suspected gram

167 All strains were resistant to ceftazidime, gentamicin, and tobramycin; 96% were resist

168 oxime, cefotaxime, cefepime, cefodizime, and ceftazidime; group B, positive responses to aminocephalo

169 lyze cephalosporins including cefuroxime and ceftazidime has been determined by X-ray crystallography

170 Imipenem and ceftazidime have different specificities for penicillin-

171 hanisms of action-meropenem, gentamicin, and ceftazidime-highlighting the versatility of this platfor

172 o a greater degree than were ceftolozane and ceftazidime; however, concentrations for all antibiotics

173 gards the primary structure requirements for ceftazidime hydrolysis by beta-lactamase.

174 termined that acylation is rate-limiting for ceftazidime hydrolysis by KPC-2, whereas deacylation is

175 Mutants that were selected for optimal ceftazidime hydrolysis contained a conserved Ala at posi

176 region of the P99 enzyme result in increased ceftazidime hydrolysis suggesting the loop is an importa

177 ydrolysis when present alone but antagonizes ceftazidime hydrolysis when it is combined with the G238

178 Thus, the A237G substitution increases ceftazidime hydrolysis when present alone but antagonize

179 the residue positions that are critical for ceftazidime hydrolysis.

180 ctive site omega loop were found to increase ceftazidime hydrolytic activity and decrease ampicillin

181 sts between enzyme instability and increased ceftazidime hydrolytic activity in the ceftazidime-selec

182 7 triple mutant, selected for high levels of ceftazidime hydrolytic activity, provides an example of

183 A was defined by resistance to piperacillin, ceftazidime, imipenem, and FQ.

184 spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were

185 tance to two antibiotics among piperacillin, ceftazidime, imipenem, colistine, and fluoroquinolones (

186 -piperacillin, imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-tazobactam, and imipe

187 eatment included intravitreal vancomycin and ceftazidime in 59 of 63 (94%) eyes and intravitreal vanc

188 stance to the third generation cephalosporin ceftazidime in bacterial pathogens expressing AmpC.

189 in the level of resistance to the antibiotic ceftazidime in comparison to that of the parental wild-t

190 Resistance to moxifloxacin and ceftazidime in cultured isolates at baseline and monthly

191 tient-days ranged from 0.2 (for colistin and ceftazidime in P. aeruginosa and for carbapenems in Kleb

192 substrate, reveals that the conformation of ceftazidime in the active site differs from that of subs

193 omycin was significantly more effective than ceftazidime in the treatment of nosocomial SBP (86.7 vs.

194 to compare meropenem plus daptomycin versus ceftazidime in the treatment of nosocomial SBP.

195 concluded that the intraperitoneal dosing of ceftazidime in these patients is an equally effective an

196 catalytic activity toward ampicillin and/or ceftazidime in vivo.

197 TEM(pTZ19-3) Glu166Arg/Met182Thr mutant for ceftazidime increased by at least 110-fold and the acyla

198 ation cephalosporins, such as cefotaxime and ceftazidime, increasing hospital mortality rates.

199 Ceftazidime/inhibitor resistant mutants hyperproduce L1,

200 Seven patients were given 1 gm of ceftazidime intravenously, and 1 wk later, the same dose

201 either anti-CD14 monoclonal antibody without ceftazidime, isotype control monoclonal antibody without

202 hogens to the third generation cephalosporin ceftazidime; it may serve as a lead compound for drug di

203 hat the best of the reversible inhibitors, a ceftazidime-like boronic acid compound, binds to CTX-M-1

204 These criteria (reduction of the ceftazidime MIC by > 2 log2 dilution steps in the presen

205 For the N+2 panel, ceftazidime MICs of >/=4 microg/ml correctly identified

206 ntibiotic-resistant Gram-negative organisms (ceftazidime minimal inhibitory concentration of > 16 mic

207 ed resistance to the oxyimino-cephalosporin, ceftazidime (minimum inhibitory concentration; 32-->128

208 inutes to different antibiotics, gentamicin, ceftazidime, nitrofurantoin, nalidixic acid, ofloxacin.

209 ) and Pseudomonas aeruginosa (30%); 28% were ceftazidime-non-susceptible.

210 for the primary efficacy analyses; 19.6% had ceftazidime-nonsusceptible baseline pathogens.

211 h treatments showed similar efficacy against ceftazidime-nonsusceptible pathogens.

212 ory test was positive; i.e., the BMD MICs of ceftazidime or cefotaxime decreased by >/=3 doubling dil

213 n zone diameters increased by >/=5 mm around ceftazidime or cefotaxime disks in the presence of CA.

214 eae isolated over a 6-month period for which ceftazidime or ceftriaxone MICs were greater than 1 micr

215 phylococcus aureus, a second drug was added (ceftazidime or piperacillin/tazobactam for P. aeruginosa

216 beta-lactamase resistant beta-lactams (e.g., ceftazidime) or avoid mechanism-based inhibitors (e.g.,

217 group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was associated with bacteremi

218 tazidime, anti-CD14 monoclonal antibody with ceftazidime, or isotype control antibody with ceftazidim

219 terial isolates to vancomycin, amikacin, and ceftazidime over a 23-year period.

220 ect, which enhances conversion of drugs like ceftazidime, penicillins, and imipenem.

221 tazidime-avibactam (a combination of 2000 mg ceftazidime plus 500 mg avibactam, administered via a 2-

222 es for ampicillin and nitrocefin, hydrolyzed ceftazidime poorly, and hydrolyzed imipenem more efficie

223 hat the R164S substitution in KPC-2 enhances ceftazidime resistance by proceeding through "covalent t

224 ality of the resistant strains suggests that ceftazidime resistance due to TEM-10 is now endemic in C

225 The molecular basis of ceftazidime resistance in 2 isolates of Klebsiella pneum

226 Both inhibitors reverse ceftazidime resistance in S. maltophilia because, unlike

227 ing 1992 and 1993 and a two-fold increase in ceftazidime resistance of the Pseudomonas species.

228 lebsiella pneumoniae that either transferred ceftazidime resistance or showed sulbactam enhancement o

229 common 54-kilobase plasmid, which conferred ceftazidime resistance via the ESBL TEM-10, and mediated

230 wild-type B. pseudomallei demonstrated that ceftazidime resistance was due to deletion of a gene enc

231 nant enzyme, TEM-10, was responsible for the ceftazidime resistance.

232 egies to a population with 15% prevalence of ceftazidime-resistance and 5% imipenem-resistance, RMD p

233 vancomycin-resistant enterococci (VRE), and ceftazidime-resistant (CAZ(r)) and ciprofloxacin-resista

234 hospital patients infected or colonized with ceftazidime-resistant E coli, K pneumoniae, or both were

235 urvey, 18 of 39 patients were colonized with ceftazidime-resistant E coli; prior receipt of ciproflox

236 ere were fewer acquired infections caused by ceftazidime-resistant Enterobacteriaceae (0.8 per thousa

237 alternative to carbapenems in patients with ceftazidime-resistant Enterobacteriaceae and P aeruginos

238 plicated intra-abdominal infection caused by ceftazidime-resistant Enterobacteriaceae or Pseudomonas

239 ents who were infected and/or colonized with ceftazidime-resistant Escherichia coli, Klebsiella pneum

240 We prospectively studied the acquisition of ceftazidime-resistant gram-negative bacilli (CAZ-RGN) in

241 nalysed in all patients who had at least one ceftazidime-resistant Gram-negative pathogen, as confirm

242 complicated intra-abdominal infection due to ceftazidime-resistant Gram-negative pathogens.

243 ceftazidime-avibactam plus metronidazole for ceftazidime-resistant infections was comparable to that

244 ence of patient infection or colonization by ceftazidime-resistant Klebsiella during 1995 (control pe

245 ied by a 44.0% reduction in the incidence of ceftazidime-resistant Klebsiella infection and colonizat

246 ontrol study to describe the epidemiology of ceftazidime-resistant Klebsiella pneumoniae and Escheric

247 nonsignificant decrease in the proportion of ceftazidime-resistant organisms acquired late (beyond 72

248 y confined to an outbreak of gentamicin- and ceftazidime-resistant organisms caused by contaminated a

249 re substantial decrease in the proportion of ceftazidime-resistant organisms derived from species kno

250 ity (number of isolates/100 patient-days) of ceftazidime-resistant organisms increased through the co

251 rom the sputum of 65 children colonised with ceftazidime-resistant P aeruginosa.

252 ctions caused by ceftazidime-susceptible and ceftazidime-resistant pathogens.

253 case of chronic endophthalmitis caused by a ceftazidime-resistant Rhizobium radiobacter strain in a

254 genomic deletion comprising 49 genes in the ceftazidime-resistant strains.

255 tazidime-susceptible isolates and subsequent ceftazidime-resistant variants.

256 ection of vancomycin-amikacin and vancomycin-ceftazidime, respectively, which resulted in complete re

257 ptible by routine testing to ceftriaxone and ceftazidime, respectively.

258 Ceftazidime restriction resulted in a small but nonsigni

259 Vancomycin and ceftazidime seem to be excellent empiric antibiotics for

260 eased ceftazidime hydrolytic activity in the ceftazidime-selected omega loop mutants.

261 structure to create additional space for the ceftazidime side chain.

262 Treatment of bacteria with the antibiotic ceftazidime significantly enhanced LP release.

263 Infections caused by ceftazidime sodium-resistant gram-negative bacteria that

264 The Etest ESBL screen test with the ceftazidime substrate appears to be a useful method for

265 acy was similar against infections caused by ceftazidime-susceptible and ceftazidime-resistant pathog

266 imilar to the regimen's own efficacy against ceftazidime-susceptible infections (82.0%).

267 six patients with melioidosis found initial ceftazidime-susceptible isolates and subsequent ceftazid

268 panel type 32) that included cefotaxime and ceftazidime tested alone or with a fixed concentration o

269 me CTX-M-16 is eightfold more active against ceftazidime than the pseudo-wild-type CTX-M-14 but is 1.

270 mutant formed a stable covalent complex with ceftazidime that remained intact for the entire duration

271 When combined with ceftazidime, the novel non-beta-lactam beta-lactamase in

272 as aeruginosa, in the presence or absence of ceftazidime therapy, and with Klebsiella pneumoniae.

273 period 1 (baseline period) (1,323 patients), ceftazidime; time period 2 (1,243 patients), ciprofloxac

274 e in the minimal inhibitory concentration of ceftazidime to 64 mug/mL.

275 Binding of either carbenicillin or ceftazidime to purified PBP3 increases the thermostabili

276 In the ceftazidime-tobramycin group, 32 (55%) evaluable patient

277 reated patients and in 42 (72%) of 58 of the ceftazidime-tobramycin-treated patients (p = .04).

278 ixty-three meropenem-treated patients and 58 ceftazidime-tobramycin-treated patients were eligible fo

279 (11/18) versus 0% (0/10) in Pseudomonas- and ceftazidime-treated rats; and 64% (9/14) versus 13% (2/1

280 This provides one explanation for ceftazidime treatment failure, and may be a frequent but

281 antibody-treated animals in the presence of ceftazidime treatment.

282 antimicrobial agents, including ampicillin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin,

283 s based on the reduction of imipenem (IP) or ceftazidime (TZ) MICs in the presence of EDTA or 2-merca

284 Despite a 96% reduction in ceftazidime use, the incidence density (number of isolat

285 tazobactam (VM error, 9.3%; m error, 12.9%), ceftazidime (VM error, 6.2%; m error, 11.4%), cefepime (

286 in which antibiotic use was not controlled, ceftazidime was prohibited unless the patient's microbio

287 Ceftazidime was the only agent to which a number of spec

288 dime and with a transition-state analogue of ceftazidime were determined by X-ray crystallography to

289 ed levels of resistance to the cephalosporin ceftazidime were identified in a set of beta-lactamase d

290 individual swab sites when mLAM plates with ceftazidime were inoculated after a 24-h enrichment peri

291 tions associated with enhanced resistance to ceftazidime were targetted to the 19-amino acid Omega-lo

292 contained vancomycin and either aztreonam or ceftazidime were used as the selective medium.

293 gated the disposition and bioavailability of ceftazidime when it was given intraperitoneally.

294 efazolin, cefepime, and, to a lesser extent, ceftazidime, which neither have significant antienteroco

295 ption was B. pseudomallei in the presence of ceftazidime, which required >10 h of incubation.

296 f ceftazidime alone compared with the MIC of ceftazidime with clavulanic acid (2 micrograms/ml) to fa